<SEC-DOCUMENT>0001213900-18-000332.txt : 20180110
<SEC-HEADER>0001213900-18-000332.hdr.sgml : 20180110
<ACCEPTANCE-DATETIME>20180110083046
ACCESSION NUMBER:		0001213900-18-000332
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180109
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180110
DATE AS OF CHANGE:		20180110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OptimizeRx Corp
		CENTRAL INDEX KEY:			0001448431
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-BUSINESS SERVICES, NEC [7389]
		IRS NUMBER:				261265381
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-53605
		FILM NUMBER:		18520368

	BUSINESS ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
		BUSINESS PHONE:		248-651-6558

	MAIL ADDRESS:	
		STREET 1:		400 WATER ST., STE. 200
		CITY:			ROCHESTER
		STATE:			MI
		ZIP:			48307
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k010918_optimizerxcorp.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
January 9, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>OptimizeRx Corporation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1.5pt solid">Nevada</TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1.5pt solid">000-53605</TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1.5pt solid">26-1265381</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or other jurisdiction<BR>
    of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(I.R.S. Employer<BR>
    Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1.5pt solid">400 Water Street, Suite 200, Rochester,
    MI</TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; border-bottom: Black 1.5pt solid">48307</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Registrant&rsquo;s telephone number, including area code: <U>248.651.6568</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed since last report)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&nbsp;&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 8 &ndash; Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><B>Item 8.01</B></TD><TD><B>Other Events</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2018, we issued a press release announcing an
expanded partnership with Allscripts Healthcare. A copy of the press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item 8.01 of this Current
Report on Form 8-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SECTION 9 &ndash; Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.75in"><B>Item 9.01</B></TD><TD><B>Financial Statements and Exhibits</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="f8k010918ex99-1_optimizerx.htm">Press release, dated January 9, 2018</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>OptimizeRx Corporation</B></FONT></TD>
    <TD STYLE="width: 65%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Douglas Baker</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Douglas Baker</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: January 10, 2018</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k010918ex99-1_optimizerx.htm
<DESCRIPTION>PRESS RELEASE, DATED JANUARY 9, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="background-color: white"><B>OptimizeRx
Expands Exclusive Partnership with Allscripts for Prescription Cost <BR>
Savings and Real-time Messaging at Point-of-Care</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Rochester,
MI (January 9, 2018) &mdash;</B> <U>OptimizeRx Corp.</U> (OTCQB: OPRX)</FONT>, the nation&rsquo;s leading provider of digital health
messaging, has expanded its partnership with Allscripts Healthcare (NASDAQ:MDRX) which now includes a variety of real-time messaging
to Allscripts ambulatory platforms. The agreement includes financial, informational, and clinical messaging delivered at the point-of-care
through Allscripts ePrescribe&trade;, Allscripts Professional EHR&trade; and Allscripts TouchWorks<SUP>&reg;</SUP> EHR solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Our goal at OptimizeRx is to help make medications more
affordable, encourage greater adherence, and provide important clinical information,&rdquo; commented Miriam Paramore, president
of OptimizeRx. &ldquo;Supported by our pharma partners, OptimizeRx and Allscripts continue to empower healthcare providers to make
better decisions and deliver better, more affordable care for healthier patients, populations and communities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Allscripts&rsquo; industry leading electronic health record
(EHR) and ePrescribing (eRx) network totals more than 180,000 physicians across 45,000 ambulatory facilities, 2,500 hospitals and
17,000 post-acute organizations. In 2017, Allscripts achieved an industry-leading milestone of one billion data exchange transactions
through its platform &ndash; the most in a single year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRx&rsquo;s growing EHR and eRx network now reaches more
than 500,000 healthcare providers (HCPs) in the U.S., making it the healthcare industry&rsquo;s largest point-of-prescribe network.
It delivers real-time access to financial assistance, education, and critical clinical information from pharma companies to HCPs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Our long-running relationship with Allscripts, a recognized
global leader in healthcare information technology, reflects the unmatched value proposition we offer to our EHR and pharma manufacturer
partners,&rdquo; said William Febbo, CEO of OptimizeRx. &ldquo;Allscripts&rsquo; continued innovation around real-time messaging
on its network helps sets the stage for stronger revenue growth and pharma partner relationships in the New Year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About OptimizeRx</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">OptimizeRx<SUP>&reg;</SUP> (OTCQB: OPRX)
is the nation&rsquo;s leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel
for pharma companies to communicate with healthcare providers. The company&rsquo;s cloud-based solution supports patient adherence
to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information.
The company&rsquo;s network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more
than half a million healthcare providers access to these benefits within their workflow at the point of care. For more information,
follow the company on <U>Twitter</U>, <U>LinkedIn</U> or visit <U>www.optimizerx.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B>Important Cautions
Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This press release contains
forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E
of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The
words &lsquo;estimate,&rsquo; &lsquo;possible&rsquo; and &rsquo;seeking&rsquo; and similar expressions identify forward-looking statements, which speak only as to
the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements,
whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from
those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>OptimizeRx Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Doug Baker, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Tel (248) 651-6568 x807</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">dbaker@optimizerx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>OptimizeRx Investor
Relations:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Ron Both, CMA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">Tel (949) 432-7557</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">oprx@cma.team</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R /L# 2(  A$! Q$!_\0
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M3^"3]D?_ (."?VW_ -D_XFQ_"G]N;1_$?Q@\%Z1JJ:+XRTWQSX<C\(?'CP
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MY_(O_P &M7BNUT7]J+]I9)[>1_/^ .DW"L#*0!)\0M$Q'M@M[A]P$))8J%Y
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M&-GSKV/_ !#&CR4U%J<:BJW<^:VJT5ET:,W_ +LO^OK/[[_!NJZ-X5\$>#-
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MM"\0^"O"/VV:PA70)':P_MG2[Z4SH#"UU/.H;>&S\G?M2_\ !T#JWB_0]/\
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MW%A<V,T;VT]E/;.]O-:RQ/!+ S0O&T;%245+VCZ+]0/R$_X)I>'] U']I_\
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**_1S<**** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
